InFocus Clinical Research today announced it has been ranked No. 434 on the 2025 Inc. 5000 list, a significant leap from its position at No. 724 in 2024. The Inc. 5000 recognizes the fastest-growing ...

Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial ...

ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And DoneTM ...

ANI Pharmaceuticals' Q2 2025 earnings report highlights record revenues, strong Cortrophin Gel demand, and raised guidance.

Meditherapy Retinal Skin Booster Serum Meditherapy's Retinal Skin Booster Serum Hits #1 on Amazon Prime Day, Loved for Its Gentle, Multi-Ta ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...

We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust interest from retina specialists and ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.

A petition to get Larochelle a Victoria Cross has been submitted to the House of Commons by Nipissing-Timiskaming MP Pauline ...

GAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024. Net loss (GAAP) ...

SHOPPING: Every small business needs tech - whether it's work phones, laptops, monitors or headphones - in the digital world, ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.